Table 1.
Treatment | Pathology | Clinical score*
|
||
---|---|---|---|---|
8 dpt | 19 dpt | 42 dpt | ||
Vehicle | Inflamm. | 3.4* | 2.5 | 2.3 |
Demyel. | 2.6 | 2.6 | 1.9 | |
2.0 mg GGF2 s.c. | Inflamm. | 1.1 | 2.2 | 1.8 |
Demyel. | 0.4 | 1.6 | 0.7 | |
2 mg GGF2 i.v. | Inflamm. | 2.2 | 2.4 | † |
Demyel. | 1.0 | 1.7 | † | |
1 mg GGF2 i.v. | Inflamm. | 3.0 | 2.3 | 2.4 |
Demyel. | 2.2 | 1.9 | 2.2 |
Animals scored on scale of 0–5. Each score represents the mean of 18 slides per animal from 9 levels of the neuraxis.
No survivors in this i.v. group. Lower dosing via the i.v. route and s.c. administration at all dose levels tested did not result in any deaths.